Multiple Sclerosis Market Outlook 2034 | Key Players: Immune Response BioPharma Inc., Clene Nanomedicine, Sanofi, Merck Healthcare KGaA, TG Therapeutics, Inc., Apimeds Inc., Bayer HealthCare, Novartis, Biogen, Alkermes, Genentech

The dynamics of the Multiple Sclerosis (MS) market are expected to shift in the coming years with the anticipated launch of new therapies, including NeuroVax (Immune Response BioPharma) and CNM-Au8 (Clene Nanomedicine). Additionally, increasing research and development efforts, along with the growing prevalence of MS, are likely to drive market growth during the forecast period.

The MS treatment market presents a promising outlook, as it continues to evolve with the introduction of novel therapies recently designated by the FDA for treating the condition. However, comprehensive multicenter trials are still needed to better understand the overall patterns of MS and treatment responses. The combination of rising disease prevalence, upcoming innovative therapies, and heightened awareness will contribute to market expansion in the years ahead.

DelveInsight's report, "Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast 2034," provides a thorough analysis of the disease, detailing historical and projected epidemiology, as well as market size, share, and trends across the seven major markets (7MM), which include the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

This report covers emerging drugs, current treatment practices, market shares of individual therapies, and the projected market size from 2020 to 2034. It also evaluates current treatment algorithms, key drivers and barriers affecting market growth, and unmet medical needs to identify opportunities and assess the market's potential.

Recent breakthrough in the multiple sclerosis market:

On October 2, 2024, SetPoint Medical announced that it has received Investigational Device Exemption (IDE) approval from the FDA to study its proprietary neuroimmune modulation platform in individuals with relapsing-remitting multiple sclerosis (RRMS). This approval represents a significant advancement for the clinical-stage healthcare company focused on chronic autoimmune diseases.

On September 16, 2024, Roche received FDA approval for OCREVUS ZUNOVO™ (ocrelizumab & hyaluronidase-ocsq) for the treatment of relapsing and primary progressive multiple sclerosis (MS). This marks the first subcutaneous injection for both forms of MS, which can be administered by a healthcare professional twice a year in approximately 10 minutes, thus broadening treatment options for MS patients.

Multiple Sclerosis Overview

Multiple Sclerosis (MS) is an unpredictable autoimmune disease that impacts the central nervous system. In MS, the body's immune system mistakenly produces cells and proteins (antibodies) that attack myelin, the fatty substance that protects nerve fibers. This condition is typically marked by episodes of neurological impairment followed by periods of remission.

The damage to myelin leads to the formation of scar tissue (sclerosis), often accompanied by injury to the nerve fibers themselves. When the myelin sheath or nerve fibers are compromised, nerve impulses traveling to and from the brain and spinal cord can become distorted or interrupted.

Symptoms of MS generally manifest in individuals during their late 20s and may include visual and sensory disturbances, limb weakness, difficulties with gait, and bladder and bowel issues. Initially, patients may experience partial recovery, but over time, many develop progressive disability.

Those affected by MS can experience a wide range of symptoms that impact them physically, emotionally, mentally, and psychologically. The severity and types of symptoms vary significantly among individuals.

MS is classified into four major categories: Relapsing-Remitting MS, Secondary-Progressive MS, Primary-Progressive MS, and Progressive-Relapsing MS.

Multiple Sclerosis Market Key Facts

In 2023, there were approximately 1.2 million prevalent cases of multiple sclerosis across the 7MM. The increase in cases can be attributed to improved diagnosis and screening, limited access to genetic counseling and family planning, and a lack of public awareness.

According to DelveInsight's analysis, in the US, there were 37 cases in the age group of 0-18 years and around 728,000 cases among those aged 19 and older, with these numbers expected to change during the study period from 2020 to 2034.

In the EU4 and the UK, Germany reported the highest number of multiple sclerosis cases, totaling approximately 210,000 in 2023, with projections indicating further changes in these figures during the same study period.

In Spain, the phenotype-specific prevalent cases of multiple sclerosis in 2023 were 826 for Clinically Isolated Syndrome, 34,786 for Relapsing-Remitting MS (RRMS), 7,205 for Secondary Progressive MS (SPMS), and 3,075 for Primary Progressive MS (PPMS). These numbers are anticipated to increase during the forecast period from 2024 to 2034.

Among the currently approved treatments, Ocrevus is expected to achieve the largest market share in the US by 2034. With the anticipated approval of new therapies during the forecast period, the overall multiple sclerosis therapeutic market is projected to grow significantly at a substantial CAGR.

The market's growth is expected to be driven primarily by advancements in diagnostic techniques, an increase in product launches, and ongoing research in pharmaceutical treatments.

Multiple Sclerosis Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Multiple Sclerosis market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Multiple Sclerosis market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Multiple Sclerosis Epidemiology Assessment

In 2023, there were approximately 728,000 prevalent cases of multiple sclerosis in the US, with significant changes expected by 2034.

In Germany, the cases were divided by gender, revealing about 61,000 cases in males and 150,000 in females.

In the UK, analysis by phenotype showed a marked difference, with a higher prevalence of Relapsing-Remitting MS (RRMS) compared to Clinically Isolated Syndrome (CIS), Secondary-Progressive MS (SPMS), and Primary-Progressive MS (PPMS). Approximately 80,000 cases of RRMS were recorded in 2023, and these numbers are projected to fluctuate during the study period from 2020 to 2034.

France had around 79,000 prevalent cases of multiple sclerosis in 2023, with further changes anticipated by 2034.

Japan recorded approximately 5,000 prevalent cases in 2023, and these figures are also expected to vary by 2034.

The Report Covers the Multiple Sclerosis Epidemiology, Segmented by -

Total Prevalent Cases of Multiple Sclerosis in the 7MM (2020-2034)
Phenotype-specific prevalent cases of Multiple Sclerosis in the 7MM (2020-2034)
Prevalence of Multiple Sclerosis based on Age in the 7MM (2020-2034)
Prevalence of Multiple Sclerosis based on Gender in the 7MM (2020-2034)
EDSS in the 7MM (2020-2034)

Multiple Sclerosis Market

The current treatment approach for multiple sclerosis (MS) primarily aims to slow disease progression and facilitate recovery from attacks. Treatment strategies are typically based on the disease's phenotypes and disability criteria, such as the Expanded Disability Status Scale (EDSS). Many patients with mild symptoms may not require treatment at all.

While there is no definitive cure for MS, recent trends in the market have shown a significant increase in the use of disease-modifying therapies (DMTs).

Management of MS attacks is usually symptomatic and includes the following medications:

- Corticosteroids: Drugs like oral prednisone and intravenous methylprednisolone are prescribed to reduce nerve inflammation. Common side effects can include insomnia, elevated blood pressure and glucose levels, mood swings, and fluid retention.

- Plasma exchange (plasmapheresis): This procedure involves removing the liquid part of the blood (plasma) and separating it from blood cells. The cells are then combined with a protein solution (albumin) and reinfused into the body. Plasma exchange is often used for patients who do not respond to steroids.

The primary focus of the market is on treatments that modify disease progression, which aim to enhance progression-free survival and improve quality-adjusted life years. These are collectively known as disease-modifying treatments (DMTs) and are tailored to the four clinical phenotypes of MS.

Many DMTs carry considerable health risks, so selecting the appropriate therapy requires careful consideration of various factors, including the duration and severity of the disease, past treatment effectiveness, other health conditions, costs, and family planning considerations. The multiple sclerosis market has a robust pipeline, with leading pharmaceutical companies developing potential candidates to address existing unmet needs.

Multiple Sclerosis Drugs Uptake and Pipeline Development Activities

The drug uptake section examines the adoption rates of recently launched or upcoming potential drugs in the Multiple Sclerosis market during the study period. This analysis includes the market uptake of individual drugs, patient uptake by therapy, and sales figures for each medication.

Additionally, the therapeutics assessment section highlights which drugs are experiencing the fastest uptake and explores the reasons for their widespread use. It also compares the drugs based on their market share.

The report further includes an overview of pipeline development activities for Multiple Sclerosis. It offers valuable insights into various therapeutic candidates at different stages of development, along with key companies involved in creating targeted therapies. Recent developments such as collaborations, acquisitions, mergers, licensing agreements, and other relevant information regarding emerging therapies are also analyzed.

Learn How the Multiple Sclerosis Market Will Evolve by 2034 @ https://www.delveinsight.com/sample-request/multiple-sclerosis-market

Some of the Leading Companies in the Multiple Sclerosis Therapeutics Market Include:

Immune Response BioPharma, Inc.
Clene Nanomedicine
Sanofi
Merck Healthcare KGaA
TG Therapeutics, Inc.
Apimeds Inc.
Bayer HealthCare
Novartis
Biogen
Alkermes
Genentech
And Many Others

Multiple Sclerosis Emerging Drugs Covered in the Report Include:

NeuroVax (Immune Response BioPharma, Inc.)
CNM-Au8 (Clene Nanomedicine)
Tolebrutinib (SAR442168) (Sanofi)
Evobrutinib/M2951 (Merck Healthcare KGaA)
Ublituximab (TG Therapeutics, Inc.)
ALKS 8700 (Alkermes/Biogen)
Arbaclofen (Arbaclofen ER) (Osmotica Pharmaceutical)
Masitinib (AB Science)
Fenebrutinib (Genentech)
And Many Others

Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More: https://www.delveinsight.com/sample-request/multiple-sclerosis-market

Table of Contents

1. Key Insights

2. Executive Summary

3. Multiple Sclerosis Competitive Intelligence Analysis

4. Multiple Sclerosis Market Overview at a Glance

5. Multiple Sclerosis Disease Background and Overview

6. Multiple Sclerosis Patient Journey

7. Multiple Sclerosis Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Multiple Sclerosis Treatment Algorithm, Current Treatment, and Medical Practices

9. Multiple Sclerosis Unmet Needs

10. Key Endpoints of Multiple Sclerosis Treatment

11. Multiple Sclerosis Marketed Products

12. Multiple Sclerosis Emerging Drugs and Latest Therapeutic Advances

13. Multiple Sclerosis Seven Major Market Analysis

14. Attribute Analysis

15. Multiple Sclerosis Market Outlook (In US, EU5, and Japan)

16. Multiple Sclerosis Access and Reimbursement Overview

17. KOL Views on the Multiple Sclerosis Market

18. Multiple Sclerosis Market Drivers

19. Multiple Sclerosis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Contact Us:
Kritika Rehani
krehani@delveinsight.com
+14699457679
www.delveinsight.com

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.